Related Experiment Video
Updated: Nov 22, 2025
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
7.6K
Chemotherapy and Radiation-Associated Cardiac Autonomic Dysfunction.
Alexandra E Teng1, Benjamin Noor2, Olujimi A Ajijola3,4
1Division of Cardiology, Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.
Current Oncology Reports
|January 8, 2021
Summary
Cardiovascular autonomic dysfunction (AD) is a growing concern in cancer survivors. This review explores its features, diagnosis, causes, and treatments, highlighting the need for further research in this population.
Area of Science:
- Cardiology
- Oncology
- Neurology
Background:
- Cardiovascular autonomic dysfunction (AD) is increasingly recognized in cancer survivors.
- Understanding its mechanisms and incidence in this population remains limited.
Purpose of the Study:
- To review the clinical features, diagnostic methods, proposed mechanisms, and treatments for cardiovascular AD in cancer survivors.
- To highlight the current gaps in knowledge and areas for future research.
Main Methods:
- Literature review of existing studies on cardiovascular AD in cancer survivors.
- Synthesis of information on diagnostic modalities and proposed etiological factors.
- Examination of current treatment strategies extrapolated from other conditions.
Main Results:
- Cardiovascular AD in cancer survivors is likely multifactorial, potentially involving chemoradiation, inflammation, and paraneoplastic syndromes.
- It may serve as an early marker for global cardiomyopathy.
- Current treatments are extrapolated and lack specific study in cancer survivors.
Conclusions:
- Cardiovascular AD significantly impacts cancer survivors' quality of life and survival.
- Diagnostic tools have limitations but offer objective markers.
- Further research is crucial to elucidate mechanisms and develop targeted therapies for cancer survivors.
Keywords:
Autonomic dysfunctionAutonomic testingBaroreflexCardio-oncologyCardiologyChemoradiationChemotherapyDysautonomia cancer survivorshipHeart rate variabilityOncologyOrthostatic hypotensionParasympatheticPeripheral neuropathyPostural orthostatic tachycardiaPresyncopeRadiation therapySympatheticSyncopeTachycardiaTilt testValsalvaMore Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
938
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
938
01:18Disorders of the Autonomic Nervous System
1.1K
The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's...
Raynaud's disease, also known as Raynaud's...
1.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
672
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
672
01:30Cardiomyopathy II: Dilated Cardiomyopathy
157
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
157
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
207
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
207
01:22Heart Failure VI: Adjunct Therapies
109
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
109